Método para la obtención de un extracto con propiedades anti-hipertensivas, anti-hiperlipidémicas y antioxidantes

[EN] The present invention relates to a method for producing an extract of Arthrospira platensi characterised by comprising the following steps: a) incubating the Arthrospira platensi biomass in water or in an aqueous solution buffered at a pH of 6.5 and at a temperature of 30°C in the presence of the enzyme alkalase; and b) separating the biomass from the solution obtained in step a) to obtain the extract. The aqueous extract thus obtained is a concentrate of amino acids, low molecular weight peptides and polyphenols, amongst other antioxidants. The extract has numerous therapeutic applications, and can be used to prevent and treat hypertension or hyperlipidaemia[ES] La presente invención se refiere a un método para la obtención de un extracto de Arthrospira platensis caracterizado por que comprende las siguientes etapas: a) incubar la biomasa de Arthrospira platensis en agua o en una solución acuosa tamponada a un pH de 6.5 y a una temperatura de 30°C en presencia de la enzima alcalasa; y b) separar la biomasa de la solución obtenida en la etapa a) para obtener el extracto. El extracto acuoso así obtenido es un concentrado de aminoácidos y péptidos de bajo peso molecular y polifenoles, entre otros antioxidantes. El extracto tiene múltiples aplicaciones terapéuticas, pudiendo usarse en la prevención y tratamiento de la hipertensión o la hiperlipidemia[FR] La présente invention concerne une méthode pour l'obtention d'un extrait de Arthrospira platensis caractérisée en ce qu'elle comprend les étapes suivantes: a) l'incubation de la biomasse de Arthrospira platensis dans de l'eau ou dans une solution aqueuse tamponnée à un pH de 6,5 et à une température de 30°C en présence de l'enzyme alcalase; et b) la séparation de la biomasse de la solution obtenue dans l'étape a) pour obtenir l'extrait. L'extrait aqueux ainsi obtenu est un concentré d'acides aminés et de peptides de faible masse moléculaire et de polyphénols, entre autres antioxydants. L'extrait a de multiples applications thérapeutiques, et peut être utilisé dans la prévention et le traitement de l'hypertension ou de l'hyperlipidémiePeer reviewedConsejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Método para la obtención de un extracto con propiedades anti-hipertensivas, anti-hiperlipidémicas y antioxidantes

Método para la obtención de un extracto con propiedades anti-hipertensivas, anti-hiperlipidémicas y antioxidantes. La presente invención se refiere a un método para obtener un extracto de Arthrospira sp. que comprende incubar Arthrospira sp. en una disolución acuosa a un pH de entre 3 y 14 en presencia de la enzima Alcalase{reg}; y separar la biomasa de la solución obtenida en la etapa a) para obtener el extracto. El extracto acuoso así obtenido es un concentrado de aminoácidos y péptidos de bajo peso molecular de fácil asimilación por el organismo, y en polifenoles entre otros antioxidantes. El extracto tiene múltiples aplicaciones terapéuticas, pudiendo usarse en la prevención y tratamiento de, por ejemplo, la hipertensión, anemia, desnutrición, hiperlipidemia, obesidad y diabetesPeer reviewedConsejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols